A Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Alzheimer's Disease Agitation
Study sponsor: Axsome Therapeutics, Inc. · AXSM
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2024-12-03Actual
Enrollment · participants456Actual
Source updated2025-12-08Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.